Durable Reduction of Low-Density Lipoprotein Cholesterol via One-Time Genetic Interventions

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2601283
Dr. Scott B. Vafai et al.

Points

Researchers conducted a Phase 1b clinical trial on 35 adults with premature coronary artery disease or heterozygous familial hypercholesterolemia to evaluate a novel gene-editing therapy.
The investigational treatment called VERVE-102 is designed as a single infusion that inactivates the hepatic PCSK9 gene to help the body clear low-density lipoprotein cholesterol.
At the highest therapeutic dose administered during the study the base-editing therapy successfully reduced dangerous low-density lipoprotein cholesterol levels by up to 62 percent.
Patient follow-up assessments conducted at 18 months post-infusion confirmed that the lipid-lowering effects were highly durable with no serious adverse events linked to the highest dose.
This molecular approach could eliminate compliance barriers associated with daily statin regimens where up to half of all patients discontinue their prescription within a single year.

Summary

This study evaluated the safety and efficacy of VERVE-102, an investigational single-dose base-editing therapy engineered to permanently inactivate proprotein convertase subtilisin-kexin type 9 (PCSK9) in the liver. Humans carrying natural loss-of-function variants of the PCSK9 gene exhibit chronically low levels of low-density lipoprotein (LDL) cholesterol and a significantly lower risk of experiencing atherosclerotic cardiovascular disease events. Because traditional daily oral or periodic injectable lipid-lowering therapies suffer from high non-adherence rates, with up to half of all patients discontinuing prescriptions within 12 months, this research sought to determine if a structural molecular intervention could mimic this natural genetic protection via a single treatment.

The Phase 1b clinical trial enrolled 35 adult participants presenting with either heterozygous familial hypercholesterolemia or premature coronary artery disease. The primary clinical objective was to analyze the safety and durability profile of the drug across escalating dose cohorts. At the maximum administered dose, the gene-editing infusion successfully decreased circulating LDL cholesterol by up to 62%. Longitudinal tracking of the cohort for up to 18 months post-infusion demonstrated highly stable, durable reductions in bad cholesterol without the development of serious treatment-related adverse events at the optimal therapeutic dosage. Minor side effects included transient, mild infusion-related reactions and brief, self-limiting elevations in liver function tests.

These findings confirm the therapeutic viability of targeting hepatic PCSK9 via base editing to achieve sustained reduction of atherogenic lipoproteic fractions. By establishing a permanent mechanism for enhanced LDL clearance, this approach offers a transformative alternative to long-term pharmacological dependence. While comprehensive phase III trials are required to establish specific hazard ratios for lifetime cardiovascular risk reduction, the baseline data indicate that VERVE-102 acts as a robust, single-intervention platform. The integration of this biotechnology into preventive cardiology could drastically improve adherence-related care gaps and optimize clinical outcomes in populations highly vulnerable to myocardial infarction and stroke.

Link to the article: https://www.nejm.org/doi/10.1056/NEJMoa2601283

References

Vafai, S. B., Täubel, J., Ashdown, T., Patel, R. S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., Gaudet, D., Lauzière, A., Brunham, L. R., Newby, D. E., Nicholls, S. J., Scott, R. S., Kerr, J., Tardif, J.-C., Lunken, C., Humphries, S. E., … Kathiresan, S. (2026). In vivo base editing of pcsk9 with verve-102 for hypercholesterolemia. New England Journal of Medicine, NEJMoa2601283. https://doi.org/10.1056/NEJMoa2601283